From the Editor

From the Desk of the Editor: Neal Shore

Neal Shore
February 26, 2018

Welcome to the timely new M0 castration-resistant prostate cancer (M0 CRPC) Center of Excellence.

Until February 2018 and the milestone ASCO GU presentations of the Phase III trials, A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER),

READ MORE

Neal Shore, MD, FACS

Neal Shore, MD, is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, and the Large Urology Group Practice Association. Dr. Shore is the editor-in-chief of UroToday’s print publication, Everyday Urology- Oncology Insights.

Videos
State-of-the-industry video lectures by leading urology experts
Conference Coverage
Recent data from conferences worldwide

CUA 2018 Prostate Cancer

ASCO 2018 Prostate Cancer

AUA 2018 Prostate Cancer

ASCO GU 2018 Prostate Cancer

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe